SWAV Shockwave Medical

Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020

Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020

SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020. Company management will host a corresponding teleconference that will be webcasted live beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. 

Investors interested in listening to the conference call may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 8889064. A live and archived webcast of the event will be available at .  

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit .

Media Contact:

Scott Shadiow

+1.317.432.9210

Investor Contact:

Debbie Kaster

 

EN
21/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shockwave Medical

 PRESS RELEASE

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said...

 PRESS RELEASE

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-W...

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch